Most MSI tumours arise sporadically [6] (74%, 97%, and 63% of endometrial, gastric, and CRC MSI cancer cases, respectively), often associated with an hypermethylation of the MLH1 promoter (all localizations) or a BRAF V600E mutation (in CRC specifically) [7]. The gene discussed is MLH1; the disease is colorectal carcinoma.